PHARMING ANNOUNCES THIRD QUARTER 2008 RESULTS
Significant progress with lead product Rhucin®

Leiden, The Netherlands, October 17, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today its results for the first nine months of 2008 ended September 30, 2008. The financial results are in line with previously reported quarterly results while significant progress has been achieved in the review and approval process of Pharming's lead product Rhucin®.

Key Developments

Financial

- Cash position of € 33.7 million (including marketable securities and excluding restricted cash) at September 30, 2008 (€ 14.1 million, at September 30, 2007),
- Total equity at September 30, 2008 of € 12.2 million (€ 34.7 million at December 31, 2007),
- Net cash used for operating activities in the first nine months of 2008 of € 17.3 million compared to € 15.2 million over the same period in 2007,
- Revenues of € 0.4 million in the first nine months of 2008 compared to € 0.6 million in the same period in 2007,
- Total costs in Q3 2008 were € 5.7 million (€ 7.5 million in Q2 2008 and € 6.5 million in Q3 2007),
- Net loss after tax of € 7.2 million in Q3 2008 (€ 8.8 million in Q2 2008 and € 6.4 million in Q3 2007).

Products

- Submission of Rhucin® registration dossier including additional data from ongoing open-label studies with European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) proceeding as planned,
- Database on Rhucin® further expanded to over 300 administrations, with more than half in repeat treatments; data confirms effectiveness and safety of Rhucin® in repeat use,
- Database on very severe attacks broadened with seven laryngeal attacks successfully treated with Rhucin®,
- Clinical study with recombinant human C1 inhibitor (rhC1INH) for treatment of antibody-mediated rejection (AMR) in kidney transplantation authorized by FDA,
- Phase I study with Prodarsan® ongoing with data expected in Q4 2008.

Corporate

- Dr Sijmen de Vries appointed as Chief Executive Officer (CEO) of Pharming as successor to Dr. Francis J. Pinto; who has taken up a non-executive position to ensure a smooth transition,
- Commercialization and supply agreement with Aslan Group AS ("Aslan") in Turkey for the marketing and distribution of food or food supplements containing Pharming's human lactoferrin product (hLF),
- Pharming's wholly owned subsidiary DNage participates in large pan-European subsidized studies in the field of biomarkers for ageing diseases,
- Pharming Included In Amsterdam Midkap Index on NYSE Euronext
- Corporate and product presentations at several investor and medical conferences in USA and Europe.

"In the third quarter of this year we continued to focus on strengthening the Rhucin® registration dossier, while maintaining a relatively low cash-need. We have included in our dossier additional data from patients receiving repeat treatments of Rhucin® as well as more treatment data from patients suffering from severe attacks. The data confirmed the effectiveness and safety of Rhucin® and we feel that we have fully addressed the concerns raised by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) earlier this year and therefore face upcoming registration filings with confidence, said Dr. Francis J. Pinto. "Meanwhile, our costs are in-line with our budget and we are keenly focused on controlling these, given the turmoil in the financial markets. Although our current liquidity position is relatively strong, we continue to look at alternative financing for our other projects."

Financial

Pharming's cash position (including marketable securities, but excluding restricted cash) at September 30, 2008 was € 33.7 million in comparison to € 14.1 million at September 30, 2007. Net cash used for operating activities of €17.3 million in the first nine months of this year is slightly higher than the amount used over the same period in 2007 (€15.2 million), largely as a result of increased costs for Research and Development, including clinical studies. Cash needs can vary from quarter to quarter depending on exact timing of payments related to, for instance, clinical trials and manufacturing. The equity position of the Company at the end of the quarter was € 12.2 million compared to € 19.4 million at June 30, 2008 and € 34.7 million at December 31, 2007. Current liabilities decreased from € 23.5 million at December 31, 2007 to € 11.3 million at September 30, 2008. This is largely as a result of the payment of € 10.2 million to Paul Royalty Fund as part of the final settlement in the restructuring of the original agreement with Paul Capital. Current liabilities at September 30, 2008 of € 11.3 million includes € 4.8 million of earn-out obligations, which the Company can decide to pay in cash or shares. Total non-current assets were € 35.3 million, almost identical to December 31, 2007.

Total costs were € 5.7 million in Q3 2008 compared to € 7.5 million in Q2 2008 and € 5.3 million in Q1 2008 and were mainly related to Research and Development, including regulatory filings. Total costs in the first nine months of 2008 amounted to € 18.5 million compared to € 17.2 million in the same period of 2007. The net loss after tax in Q3 2008 was € 7.2 million compared to € 6.4 million in Q3 2007, primarily related to the effective interest on the convertible bonds issued in Q4 2007. Revenues were € 0.4 million compared to € 0.6 million in the first nine months of 2007 and mainly attributable to grants and subsidies.

Products

Over the last few months, Pharming made significant progress with its lead product Rhucin®, particularly by the expansion of the database and the strengthening of the registration dossier. Earlier this year, the CHMP requested more data on repeat use and treatment of severe attacks. Over 300 administrations of Rhucin® have now been analyzed, of which more than half in repeat treatments. The database on very severe attacks has also been expanded and now includes seven laryngeal attacks. There are no relevant safety issues, no allergic reactions and efficacy remains very good. The Company is in discussions with the relevant authorities both in the EU and in the US on the submission of the Rhucin® registration file. Pharming hopes to submit the Biological License Application (BLA) for Rhucin® with the FDA later this year and the Market Authorization Application to EMEA shortly thereafter.

With respect to other clinical indications, Pharming successfully completed a Phase I safety study with recombinant human C1 inhibitor (rhC1INH) in healthy volunteers. The Company has recently received approval from the FDA to start clinical studies in the US with rhC1INH for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. AMR can lead to organ failure and is a significant cause of kidney transplant loss. In the FDA-approved study, Dr. Sollinger of the University of Wisconsin, Madison will study patients with AMR to compare rhC1INH against the available standard of care.

Although an independent scientific expert panel concluded that Pharming's lactoferrin product (hLF) is safe for its intended uses, the Company is still awaiting an official response from the FDA with regard to the GRAS notification (Generally Recognized As Safe) procedure for hLF.

Pharming's subsidiary DNage started a Phase I clinical study in healthy volunteers. In this study, pharmacokinetics and tolerability of single and multiple doses of Prodarsan® are evaluated. In animal models for Cockayne Syndrome, a premature ageing disorder, Pharming has already demonstrated that Prodarsan® has significant effects on life expectancy in general and more specifically on eye abnormalities associated with the disease. The Company expects to announce the results of the Phase I study in the fourth quarter of this year. Following a successful completion of this trial, Pharming will start clinical studies in patients of Cockayne Syndrome.

DNage is also participating in several projects on the identification of novel biomarkers of human ageing. Most of these projects are subsidized or paid for by government grants.

Corporate

At a recent Extraordinary Shareholders' Meeting, Dr Sijmen de Vries was appointed as Chief Executive Officer (CEO) of Pharming effective November 3, 2008. Dr de Vries is successor to Dr Francis J. Pinto who will retire at the next Annual General Meeting of Shareholders in 2009. Dr de Vries has extensive experience in pharma and biotech companies, with specific strengths built in the fields of international business development and strategic marketing.

To ensure a smooth transition, Dr Pinto will stay on as Non-Executive Chairman of the Management Board. As part of this transition plan, task forces have been set-up to focus on optimising the key aspects of Pharming's business. These task forces include a Rhucin® task force focusing on the upcoming Rhucin® filings (led by Dr Giannetti), a DNage task force focusing on the development and partnering of the DNage ageing products (led by Dr Strijker), a task force "Financing and Shareholder Value" addressing the future financing of Pharming (led by Dr Pinto) and a task force focusing on further developing the Pharming organization and 2009 plans and budgets, which will be led by Dr de Vries.

In July, Pharming and Turkish company Aslan closed a commercialization and supply agreement for Pharming's human lactoferrin product. The agreement focuses on the marketing and distribution of food or food supplements containing hLF. Pharming will supply hLF containing milk powder to Aslan, who will be responsible for the production and the design of the finished products.

During the third quarter, Pharming made several corporate and product presentations at investor and medical conferences in the USA and Europe, including the UBS Global Life Sciences Meeting in New York on September 22, 2008. Dr Pinto presented a business update at that meeting describing the progress made in the development of lead product Rhucin®. The presentation can be found on the Pharming website.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker, Investor Voice, T: +31 (0)6 537 499 59 or T: +31 (0)71 52 47 400
Julia Phillips (UK), Financial Dynamics, T: +44 (0)20 7269 7187 or T: +44 (0)7770 827 263
Samir Singh (US), Pharming Group NV, T: +1 908 720 6224
Rein Strijker, Pharming Group NV, T: +31 (0)71 52 47 400

CONSOLIDATED BALANCE SHEET

At September 30, 2008 (amounts in €'000) (unaudited)

	September 30, 2008	December 31, 2007
Goodwill	9,190	9,190
Intangible assets	19,142	18,981
Property, plant and equipment	6,599	7,098
Financial assets	200	200
Restricted cash	176	176
Non-current assets	**35,307**	**35,645**
Inventories	11,188	11,720
Other current assets	1,681	1,893
Marketable securities	3,223	3,956
Restricted cash	-	10,180
Cash and cash equivalents	30,441	50,954
Current assets	**46,533**	**78,703**
Total assets	**81,840**	**114,348**
Share capital	45,618	45,618
Share premium	182,244	182,243
Other reserves	22,091	22,110
Accumulated deficit	(237,704)	(215,280)
Total equity	**12,249**	**34,691**
Convertible bonds	52,034	49,768
Deferred tax liability	3,292	3,613
Earn-out obligations	2,654	2,315
Other	334	412
Non-current liabilities	**58,314**	**56,108**
Paul Royalty Fund	-	10,180
Trade and other payables	4,388	7,830
Earn-out obligations	4,777	4,634
Nominal interest on convertible bonds	2,005	801
Current portion of other non-current liabilities	107	104
Current liabilities	**11,277**	**23,549**
Total equity and liabilities	**81,840**	**114,348**

CONSOLIDATED INCOME STATEMENT

For the period ended September 30, 2008 (amounts in €'000, except per share data) (unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2008	2007	2008	2007
Revenues	**123**	**164**	**369**	**575**
Research and development	4,422	5,038	14,759	12,910
General and administrative	758	653	2,030	1,819
Depreciation and amortization charges	352	353	1,027	1,048
Impairment charges	-	-	177	-
Share-based compensation	156	437	512	1,437
Costs	**5,688**	**6,481**	**18,505**	**17,214**
Loss from operating activities	**(5,565)**	**(6,317)**	**(18,136)**	**(16,639)**
Effective interest convertible bonds	(1,992)	-	(5,876)	-
Interest on liability Paul Royalty Fund	-	(617)	-	(1,947)
Interest on earn-out obligations	(331)	(296)	(482)	(849)
Other interest income, net	481	204	1,651	769
Finance revenue and costs	**(1,842)**	**(709)**	**(4,707)**	**(2,027)**
Foreign currency effect on liability Paul Royalty Fund	-	564	-	856
Other foreign currency results	69	(27)	98	(79)
Other income and expenses	**69**	**537**	**98**	**777**
Loss before tax	**(7,338)**	**(6,489)**	**(22,745)**	**(17,889)**
Income tax benefit	108	62	321	192
Net loss after tax	**(7,230)**	**(6,427)**	**(22,424)**	**(17,697)**
Attributable to Equity holders of the parent	**(7,230)**	**(6,427)**	**(22,424)**	**(17,697)**
Share information:				
Basic and diluted net loss per share (€)	(0.08)	(0.07)	(0.25)	(0.19)
Weighted average shares outstanding	91,236,673	91,120,203	91,236,166	90,835,153

Number of shares outstanding at September 30, 2008 was 91,236,673.

CONSOLIDATED STATEMENT OF CASH FLOW

For the period ended September 30, 2008 (amounts in €'000) (unaudited)

	September 30, 2008	September 30, 2007
Payments of third party fees and expenses, including Value Added Tax	(15,211)	(14,756)
Net compensation paid to board members and employees	(3,310)	(2,408)
Payments of pension premiums, payroll taxes and social securities, net of grants settled	(2,361)	(1,954)
Other payments	(385)	(50)
Receipt of Value Added Tax	1,146	1,970
Interest received from cash and marketable securities	1,950	1,127
Receipt of grants	393	549
Other receipts	451	300
Net cash flows used in operating activities	**(17,327)**	**(15,222)**
Purchase of property, plant and equipment	(280)	(607)
Purchase of intangible assets	(525)	-
Net cash flows used in investing activities	**(805)**	**(607)**
Net proceeds of increase of share capital	1	1,070
Repayment to Paul Royalty Fund	(10,075)	(1,473)
Payment of nominal interest convertible bonds	(2,406)	-
Repayment of other financial liabilities	(69)	(33)
Net cash flows used in financing activities	**(12,549)**	**(436)**
Net decrease cash and cash equivalents	**(30,681)**	**(16,265)**
Cash and cash equivalents at January 1 (including restricted cash)	61,310	26,258
Exchange rate effect	(12)	(79)
Net decrease cash and cash equivalents	(30,681)	(16,265)
Cash and cash equivalents at September 30 (including restricted cash)	**30,617**	**9,914**
Liquidity information		
Cash and cash equivalents at September 30 (including restricted cash)	30,617	9,914
Marketable securities at September 30	3,223	4,166
Total liquidities at September 30	**33,840**	**14,080**